{"id":390520,"date":"2018-12-20T00:00:00","date_gmt":"2018-12-20T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0012-2018-biopharma-bladder-cancer-disease-landscape-and-forecast-g7-2018\/"},"modified":"2026-04-17T23:38:30","modified_gmt":"2026-04-17T23:38:30","slug":"dlsfon0012-2018-biopharma-bladder-cancer-disease-landscape-and-forecast-g7-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0012-2018-biopharma-bladder-cancer-disease-landscape-and-forecast-g7-2018\/","title":{"rendered":"Bladder Cancer | Disease Landscape and Forecast | G7 | 2018"},"content":{"rendered":"<p><strong>Market Outlook<\/strong><\/p>\n<p>Immune checkpoint inhibitors are revolutionizing the treatment algorithm for unresectable locally advanced or metastatic bladder cancer. Following the 2016\/7\u00a0<abbr title=\"Food and Drug Administration\">FDA<\/abbr>\u00a0approvals of five immune checkpoint inhibitors for platinum-treated patients (i.e., second\u2013 and later lines)\u2014<abbr title=\"programmed death-ligand 1\">PD-L1<\/abbr>\u00a0inhibitor Tecentriq (Roche\/Genentech\/Chugai) followed by\u00a0<abbr title=\"programmed cell death-1\">PD-1<\/abbr>\u00a0inhibitor Opdivo (Bristol-Myers Squibb) and other\u00a0<abbr title=\"programmed cell death-1\">PD-1<\/abbr>\/<abbr title=\"programmed death-ligand 1\">PD-L1<\/abbr>\u00a0inhibitors\u2014significant sales are forecast for the unresectable locally advanced or metastatic setting. There is now intense Phase II\/III pipeline activity, with some drugs in the late-phase pipeline also targeting previously untreated unresectable locally advanced or metastatic bladder cancer (i.e., first-line setting). We anticipate that several new therapies will gain approvals within the forecast period, resulting in increased therapy options.<\/p>\n<p><strong>Questions Answered<\/strong><\/p>\n<ul>\n<li>How large are the clinically and commercially relevant drug-treatable unresectable locally advanced or metastatic bladder cancer populations and how will drug-treatment rates change over time?<\/li>\n<li>What is the current state of treatment for unresectable locally advanced or metastatic bladder cancer? What are the (dis)advantages of currently marketed drugs and interviewed experts\u2019 insights on these therapies?<\/li>\n<li>What clinical needs remain unfulfilled and what opportunities can developers capitalize on?<\/li>\n<li>What pipeline products are most promising, and what sales\/uptake could they secure in the unresectable locally advanced or metastatic bladder cancer market? What are the most promising early-phase pipeline products?<\/li>\n<li>What are the drivers and constraints in the unresectable bladder cancer market, and how will the market evolve over the ten-year forecast period within the major markets?<\/li>\n<\/ul>\n<p><strong>Product Description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n","protected":false},"template":"","class_list":["post-390520","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-bladder-cancer","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390520","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390520\/revisions"}],"predecessor-version":[{"id":576669,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390520\/revisions\/576669"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390520"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}